Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 Using Generative AI
12 avr. 2023 09h00 HE
|
InSilico Medicine
New York and Hong Kong, April 12, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced...
Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19
23 févr. 2023 09h00 HE
|
InSilico Medicine
New York, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s...
Insilico Medicine Receives FDA Orphan Drug Designation for Generative AI Discovered and Designed Drug for Idiopathic Pulmonary Fibrosis
08 févr. 2023 09h00 HE
|
InSilico Medicine
New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, today announced that...
Insilico Medicine Opens Largest AI-Powered Biotechnology Research Center in the Middle East
01 févr. 2023 09h27 HE
|
InSilico Medicine
Abu Dhabi, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage artificial intelligence (AI)-driven drug discovery company, is announcing today the opening of the...
Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target
10 janv. 2023 09h00 HE
|
InSilico Medicine
New York, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of...
Insilico Medicine launches 6th generation Intelligent Robotics Lab to further accelerate its AI-driven drug discovery
05 janv. 2023 09h00 HE
|
InSilico Medicine
New York, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life...
Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2- Breast Cancer Therapy with End-to-End AI Engine
27 déc. 2022 12h30 HE
|
InSilico Medicine
New York, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's...
Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology
20 déc. 2022 09h00 HE
|
InSilico Medicine
New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company...
Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI
01 déc. 2022 09h00 HE
|
InSilico Medicine
New York, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced...
Insilico Medicine to Present at 41st Annual J.P. Morgan Healthcare Meeting
29 nov. 2022 09h00 HE
|
InSilico Medicine
New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine will present at the 41st Annual J.P. Morgan Healthcare Meeting happening Jan. 9-12, 2023 at the Westin St. Francis Hotel in San...